Perhaps this ADC will [open up] an avenue to really target that pathway in platinum-resistant ovarian cancer. This includes [patients with] heavily pretreated, mesothelin-expressing, platinum-resistant ovarian cancer and epithelial ovarian cancer, [which includes] patients who have 4 or more prior lines [of therapy]. Second to that, we are still trying to figure out if immunotherapy can be active in [patients with] ovarian cancer. I would be interested to see if this has a response rate or a profile that could be interesting in [patients with] ovarian cancer. Nonetheless, this is a particularly important patient population because there's really an unmet need in this group of patients with heavily pretreated, platinum-resistant ovarian cancer.